SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Novavax Inc. – ‘10-K’ for 12/31/23 – ‘EX-97’

On:  Wednesday, 2/28/24, at 7:30am ET   ·   For:  12/31/23   ·   Accession #:  1000694-24-7   ·   File #:  0-26770

Previous ‘10-K’:  ‘10-K’ on 2/28/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   41 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/24  Novavax Inc.                      10-K       12/31/23  114:12M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.36M 
 2: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     43K 
10: EX-10.101   Material Contract                                   HTML    340K 
 3: EX-10.28    Material Contract                                   HTML     59K 
 4: EX-10.32    Material Contract                                   HTML     41K 
 5: EX-10.33    Material Contract                                   HTML     84K 
 6: EX-10.34    Material Contract                                   HTML     38K 
 7: EX-10.35    Material Contract                                   HTML     78K 
 8: EX-10.36    Material Contract                                   HTML     38K 
 9: EX-10.37    Material Contract                                   HTML     63K 
11: EX-21       Subsidiaries List                                   HTML     29K 
12: EX-23.1     Consent of Expert or Counsel                        HTML     34K 
17: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     42K 
                Awarded Compensation                                             
13: EX-31.1     Certification -- §302 - SOA'02                      HTML     34K 
14: EX-31.2     Certification -- §302 - SOA'02                      HTML     34K 
15: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
16: EX-32.2     Certification -- §906 - SOA'02                      HTML     31K 
23: R1          Cover Page                                          HTML     95K 
24: R2          Audit Information                                   HTML     34K 
25: R3          Consolidated Statements of Operations               HTML    111K 
26: R4          Consolidated Statements of Comprehensive Loss       HTML     56K 
27: R5          Consolidated Balance Sheets                         HTML    143K 
28: R6          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
29: R7          Consolidated Statements of Changes in               HTML     85K 
                Stockholders' Equity (Deficit)                                   
30: R8          Consolidated Statements of Changes in               HTML     32K 
                Stockholders' Equity (Deficit) (Parenthetical)                   
31: R9          Consolidated Statements of Cash Flows               HTML    123K 
32: R10         Organization & Business                             HTML     34K 
33: R11         Summary of Significant Accounting Policies          HTML    120K 
34: R12         Revenue                                             HTML    107K 
35: R13         Collaboration, License, and Supply Agreements       HTML     47K 
36: R14         Cash, Cash Equivalents, and Restricted Cash         HTML     42K 
37: R15         Fair Value Measurements                             HTML     65K 
38: R16         Inventory                                           HTML     46K 
39: R17         Goodwill                                            HTML     37K 
40: R18         Leases                                              HTML    154K 
41: R19         Long-Term Debt                                      HTML     70K 
42: R20         Stockholders? Deficit                               HTML     39K 
43: R21         Stock-Based Compensation                            HTML     97K 
44: R22         Employee Benefits                                   HTML     35K 
45: R23         Other Financial Information                         HTML     64K 
46: R24         Income Taxes                                        HTML    120K 
47: R25         Commitment and Contingencies                        HTML     53K 
48: R26         Restructuring                                       HTML     39K 
49: R27         Subsequent Events                                   HTML     32K 
50: R28         Pay vs Performance Disclosure                       HTML     41K 
51: R29         Insider Trading Arrangements                        HTML     48K 
52: R30         Summary of Significant Accounting Policies          HTML    159K 
                (Policies)                                                       
53: R31         Summary of Significant Accounting Policies          HTML     65K 
                (Tables)                                                         
54: R32         Revenue (Tables)                                    HTML     84K 
55: R33         Cash, Cash Equivalents, and Restricted Cash         HTML     41K 
                (Tables)                                                         
56: R34         Fair Value Measurements (Tables)                    HTML     63K 
57: R35         Inventory (Tables)                                  HTML     47K 
58: R36         Goodwill (Tables)                                   HTML     39K 
59: R37         Leases (Tables)                                     HTML     93K 
60: R38         Long-Term Debt (Tables)                             HTML     51K 
61: R39         Stock-Based Compensation (Tables)                   HTML     95K 
62: R40         Other Financial Information (Tables)                HTML     72K 
63: R41         Income Taxes (Tables)                               HTML    122K 
64: R42         Restructuring (Tables)                              HTML     36K 
65: R43         Summary of Significant Accounting Policies -        HTML     94K 
                Additional Information (Details)                                 
66: R44         Summary of Significant Accounting Policies -        HTML     54K 
                Schedule of Concentration Risk (Details)                         
67: R45         Summary of Significant Accounting Policies -        HTML     39K 
                Schedule of Property and Equipment (Details)                     
68: R46         Revenue - Additional Information (Details)          HTML    201K 
69: R47         Revenue - Schedule of Accounts Receivable,          HTML     73K 
                Unbilled Services, and Deferred Revenue (Details)                
70: R48         Revenue - Schedule of Product Revenue (Details)     HTML     48K 
71: R49         Revenue - Schedule of Revenue Gross to Net          HTML     48K 
                Deductions Balances (Details)                                    
72: R50         Revenue - Schedule of Grant Revenue (Details)       HTML     49K 
73: R51         Collaboration, License, and Supply Agreements       HTML     87K 
                (Details)                                                        
74: R52         Cash, Cash Equivalents, and Restricted Cash -       HTML     41K 
                Schedule of Reconciliation of Cash, Cash                         
                Equivalents, and Restricted Cash (Details)                       
75: R53         Fair Value Measurements (Details)                   HTML     72K 
76: R54         Inventory - Schedule of Inventory (Details)         HTML     37K 
77: R55         Inventory - Additional Information (Details)        HTML     39K 
78: R56         Inventory - Schedule of Inventory Reserves          HTML     37K 
                (Details)                                                        
79: R57         Goodwill (Details)                                  HTML     39K 
80: R58         Leases - Additional Information (Details)           HTML     60K 
81: R59         Leases - Schedule of Supplemental Balance Sheet     HTML     68K 
                Information Related to Leases (Details)                          
82: R60         Leases - Schedule of Operating Lease Expenses       HTML     44K 
                (Details)                                                        
83: R61         Leases - Schedule of Supplemental Cash Flow         HTML     41K 
                Information of Leases (Details)                                  
84: R62         Leases - Maturities of Lease Liabilities (Details)  HTML     48K 
85: R63         Long-Term Debt - Schedule of Notes Payable          HTML     55K 
                (Details)                                                        
86: R64         Long-Term Debt - Schedule of Interest Expense       HTML     38K 
                (Details)                                                        
87: R65         Long-Term Debt - Additional Information (Details)   HTML    105K 
88: R66         Stockholders? Deficit (Details)                     HTML     75K 
89: R67         Stock-Based Compensation - Additional Information   HTML     92K 
                (Details)                                                        
90: R68         Stock-Based Compensation - Schedule of Stock-Based  HTML     39K 
                Compensation Expense (Details)                                   
91: R69         Stock-Based Compensation - Schedule of Option and   HTML     71K 
                Appreciation Rights Activity (Details)                           
92: R70         Stock-Based Compensation - Schedule of Assumptions  HTML     59K 
                Used in Estimation of Fair Value of Stock                        
                (Details)                                                        
93: R71         Stock-Based Compensation - Schedule of Restricted   HTML     61K 
                Stock Units Activity (Details)                                   
94: R72         Employee Benefits (Details)                         HTML     46K 
95: R73         Other Financial Information - Schedule of Prepaid   HTML     36K 
                Expenses and Other Current Assets (Details)                      
96: R74         Other Financial Information - Schedule of Property  HTML     49K 
                and Equipment, Net (Details)                                     
97: R75         Other Financial Information - Additional            HTML     37K 
                Information (Details)                                            
98: R76         Other Financial Information - Schedule of Accrued   HTML     41K 
                Expenses (Details)                                               
99: R77         Other Financial Information - Schedule of Other     HTML     37K 
                Current Liabilities (Details)                                    
100: R78         Income Taxes - Schedule of Company's Income (Loss)  HTML     39K  
                from Operations Before Income Tax Provision                      
                (Benefit) by Jurisdiction (Details)                              
101: R79         Income Taxes - Schedule of Components of Income     HTML     48K  
                Tax Expense (Benefit) (Details)                                  
102: R80         Income Taxes - Additional Information (Details)     HTML     54K  
103: R81         Income Taxes - Schedule of Tax Rate Differences     HTML     58K  
                (Details)                                                        
104: R82         Income Taxes - Schedule of Deferred Tax Assets and  HTML     79K  
                Liabilities (Details)                                            
105: R83         Income Taxes - Schedule of Unrecognized Tax         HTML     41K  
                Benefits Rollforward (Details)                                   
106: R84         Commitment and Contingencies (Details)              HTML     71K  
107: R85         Restructuring - Schedule of Impairment Charges      HTML     45K  
                (Details)                                                        
108: R86         Restructuring - Narrative (Details)                 HTML     42K  
109: R87         Subsequent Events (Details)                         HTML     34K  
111: XML         IDEA XML File -- Filing Summary                      XML    188K  
114: XML         XBRL Instance -- nvax-20231231_htm                   XML   2.30M  
110: EXCEL       IDEA Workbook of Financial Report Info              XLSX    229K  
19: EX-101.CAL  XBRL Calculations -- nvax-20231231_cal               XML    249K 
20: EX-101.DEF  XBRL Definitions -- nvax-20231231_def                XML    949K 
21: EX-101.LAB  XBRL Labels -- nvax-20231231_lab                     XML   2.46M 
22: EX-101.PRE  XBRL Presentations -- nvax-20231231_pre              XML   1.48M 
18: EX-101.SCH  XBRL Schema -- nvax-20231231                         XSD    235K 
112: JSON        XBRL Instance as JSON Data -- MetaLinks              654±   960K  
113: ZIP         XBRL Zipped Folder -- 0001000694-24-000007-xbrl      Zip   1.03M  


‘EX-97’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  
Exhibit 97
Novavax, Inc.
Second Amended and Restated Recoupment Policy

1.Introduction

This Second Amended and Restated Recoupment Policy (as amended from time to time, the “Policy”) has been prepared in accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, and approved by the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) providing for the Company’s recoupment of certain incentive-based compensation paid to Covered Executives (as defined below) in the event that the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under the securities laws.

2.Administration

Administration and enforcement of this Policy is delegated to the Compensation Committee of the Board (as constituted from time to time, and including any successor committee, the “Committee”). The Committee shall make all determinations under this Policy in its sole discretion. Determinations of the Committee under this Policy need not be uniform with respect to any or all Covered Executives and will be final and binding.

3.Effective Date

This Policy shall be effective as of June 16, 2023 (the “Effective Date”) and shall apply only to Covered Compensation (as defined below) that is awarded or granted to, achieved or received by, Covered Executives on or after the Effective Date, except as otherwise agreed to by any Covered Executive.

4.Covered Executives

This Policy covers each current or former officer of the Company subject to Section 16 of the Securities Exchange Act of 1934, as amended (each, a “Covered Executive”).

5.Covered Compensation

This Policy applies to any cash-based and equity-based incentive compensation, bonuses, and awards granted, paid, earned or that become vested wholly or in part upon the attainment of any financial reporting measure (“Covered Compensation”) to Covered Executives. This Policy shall apply to any Covered Compensation received by an employee who served as a Covered Executive at any time during the performance period for that Covered Compensation.

6.Financial Restatements; Recoupment

In the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (such an accounting restatement, a “Restatement”), the Committee shall review the Covered Compensation received by a Covered Executive during the three-year period preceding the Required Financial Restatement Date as well as any transition period that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years. Regardless of whether the Company filed the restated financial statements, the Committee shall, to the full extent permitted by governing law, seek



Exhibit 97
recoupment of any Covered Compensation, whether in the form of cash or equity, awarded or paid to a Covered Executive (computed without regard to any taxes paid), if and to the extent:

a.the amount of the Covered Compensation was calculated based upon the achievement of certain financial results that were subsequently the subject of a Restatement; and

b.the amount of the Covered Compensation that would have been awarded to the Covered Executive had the financial results been properly reported would have been lower than the amount actually awarded.

If the achievement of a certain financial result was considered in determining the Covered Compensation awarded or paid, but the Covered Compensation is not awarded or paid on a formulaic basis, the Committee shall determine the amount, if any, by which the payment or award should be reduced or recouped.

For purposes of this Policy, the “Required Financial Restatement Date” is the earlier to occur of:

a.the date the Board, a committee of the Board, or any officer or officers authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement; or

b.the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.

For the avoidance of doubt, a Covered Executive will be deemed to have received Covered Compensation in the Company’s fiscal period during which the financial reporting measure specified in the award is attained, even if the Covered Executive remains subject to additional payment conditions with respect to such award.

7.Method of Recoupment

The Committee will determine, in its sole discretion, the method for recouping erroneously awarded Covered Compensation, which may include, without limitation:

a.requiring reimbursement of cash incentive compensation previously paid;

b.cancelling or rescinding some or all outstanding vested or unvested equity (and/or equity-based) awards;

c.adjusting or withholding from unpaid compensation or other set-off to the extent permitted by applicable law; and/or

d.reducing or eliminating future salary increases, cash-based or equity-based incentive compensation, bonuses, awards or severance.

8.Impracticability Exceptions

The Committee shall not seek recoupment of any erroneously awarded Covered Compensation to the extent it determines that:

a.the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of erroneously-awarded Covered Compensation to be recovered after reasonable attempt to recover such Covered Compensation;



Exhibit 97

b.recovery would violate home country law, per an opinion form counsel in the relevant jurisdiction, where that law was adopted prior to November 28, 2022; and/or

c.recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Sections 401(a)(13) and 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.

9.No Indemnification

For the avoidance of doubt, the Company shall not indemnify any Covered Executive against the loss of any erroneously awarded Covered Compensation or any Covered Compensation that is recouped pursuant to the terms of this Policy, or any claims relating to the Company’s enforcement of its rights under this Policy.

10.Severability

If any provision of this Policy or the application of any such provision to any Covered Executive shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.

11.Amendments

The Committee may amend, modify or terminate this Policy in whole or in part at any time and may adopt such rules and procedures that it deems necessary or appropriate to implement this Policy or to comply with applicable laws and regulations.

12.No Impairment of Other Remedies

The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company may have, the Company’s ability to enforce, without duplication, the recoupment provisions set forth in any separate Company policy or in any Company plan, program or agreement (each, a “Separate Recoupment Policy” and collectively, the “Separate Recoupment Policies”), or any actions that may be imposed by law enforcement agencies, regulators or other authorities. Notwithstanding the foregoing, in the event that there is a conflict between the application of this Policy to a Covered Executive in the event of a Restatement and any additional recoupment provisions set forth in a Separate Recoupment Policy to which a Covered Executive is subject, the provisions of this Policy shall control. The Company may also adopt additional Separate Recoupment Policies in the future or amend existing requirements as required by law or regulation.



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/28/24
For Period end:12/31/23
6/16/233,  4
11/28/22
 List all Filings 


41 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/09/23  Novavax Inc.                      10-Q        9/30/23   74:7M
 8/08/23  Novavax Inc.                      8-K:1,3,9   8/08/23   12:335K                                   Toppan Merrill/FA
 8/08/23  Novavax Inc.                      10-Q        6/30/23   86:9.5M
 5/09/23  Novavax Inc.                      10-Q        3/31/23   72:7.1M
 4/28/23  Novavax Inc.                      DEF 14A               12:5.8M
 4/04/23  Novavax Inc.                      8-K:5,9     3/30/23   11:302K
 2/28/23  Novavax Inc.                      10-K       12/31/22  108:16M
 1/09/23  Novavax Inc.                      8-K:5,7,9   1/05/23   14:435K                                   Toppan Merrill/FA
12/21/22  Novavax Inc.                      8-K:1,2,3,912/20/22   11:1M                                     Toppan Merrill/FA
11/09/22  Novavax Inc.                      10-Q        9/30/22   77:12M
 8/09/22  Novavax Inc.                      10-Q        6/30/22   73:7M
 5/10/22  Novavax Inc.                      10-Q        3/31/22   75:8.9M
 5/02/22  Novavax Inc.                      DEF 14A     6/16/21    1:7.2M                                   Toppan Merrill/FA
 3/01/22  Novavax Inc.                      10-K       12/31/21  111:22M
11/05/21  Novavax Inc.                      10-Q        9/30/21   76:9.1M
 8/05/21  Novavax Inc.                      10-Q        6/30/21   75:8.1M
 5/10/21  Novavax Inc.                      10-Q        3/31/21   73:7.6M
 3/01/21  Novavax Inc.                      10-K       12/31/20  109:94M
11/10/20  Novavax Inc.                      10-Q        9/30/20   87:10M                                    Toppan Merrill Bridge/FA
 8/10/20  Novavax Inc.                      10-Q        6/30/20   73:8.6M                                   Toppan Merrill/FA
 6/19/20  Novavax Inc.                      8-K:1,3,5,8 6/15/20    5:261K                                   Toppan Merrill/FA
12/31/19  Novavax Inc.                      S-3                    4:1.3M                                   Toppan Merrill/FA
11/07/19  Novavax Inc.                      10-Q        9/30/19   72:5.7M                                   Toppan Merrill/FA
 8/07/19  Novavax Inc.                      10-Q        6/30/19   72:6.5M                                   Toppan Merrill/FA
 5/09/19  Novavax Inc.                      8-K:5,9     5/08/19    2:32K                                    Toppan Merrill/FA
 3/18/19  Novavax Inc.                      10-K       12/31/18   89:9.2M                                   Toppan Merrill/FA
 5/08/17  Novavax Inc.                      10-Q        3/31/17   64:4.1M                                   Toppan Merrill/FA
 2/27/17  Novavax Inc.                      10-K       12/31/16   90:7.1M                                   Toppan Merrill/FA
11/16/16  Novavax Inc.                      8-K:5,9    11/14/16    2:66K                                    Toppan Merrill/FA
 5/05/16  Novavax Inc.                      10-Q        3/31/16   68:4.5M                                   Toppan Merrill/FA
 2/29/16  Novavax Inc.                      10-K       12/31/15   97:7.1M                                   Toppan Merrill/FA
11/09/15  Novavax Inc.                      10-Q        9/30/15   61:4.3M                                   Toppan Merrill/FA
 8/21/15  Novavax Inc.                      8-K:1,2,9   8/17/15    3:461K                                   Toppan Merrill/FA
 8/10/15  Novavax Inc.                      10-Q        6/30/15   60:4.9M                                   Toppan Merrill/FA
 2/27/15  Novavax Inc.                      10-K       12/31/14  101:9.5M                                   Toppan Merrill/FA
 4/30/14  Novavax Inc.                      DEF 14A     6/12/14    1:1.1M                                   Toppan Merrill/FA
 3/12/13  Novavax Inc.                      10-K       12/31/12   93:6.4M                                   Toppan Merrill/FA
 3/14/12  Novavax Inc.                      10-K       12/31/11   46:4.6M                                   Toppan Merrill/FA
 8/09/11  Novavax Inc.                      10-Q        6/30/11   31:3.1M                                   Toppan Merrill/FA
 7/06/10  Novavax Inc.                      8-K:5,9     7/01/10    3:110K                                   Toppan Merrill/FA
 3/16/10  Novavax Inc.                      10-K       12/31/09   14:3M                                     Toppan Merrill/FA
Top
Filing Submission 0001000694-24-000007   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 3:46:42.3pm ET